Author

Monika Iris Leschinger

Observed names: M Leschinger, M. I. Leschinger, M. Leschinger, MONIKA I. LESCHINGER, Monika I. Leschinger, Monika Leschinger

Institution: Eli Lilly (Germany)

Observed institutions: University of Helsinki, Heidelberg University, Helsinki University Hospital, Catharina Ziekenhuis, Eli Lilly (Germany), Lungenklinik Köln-Merheim, Hôpital Larrey, The Christie Hospital, Klinikum Kassel, Wythenshawe Hospital, Instituto Nazionale Tumori Regina Elena, University of Turin, University of Aveiro, European Institute of Oncology

OpenAlex ID: A5082718614

Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer

2011 · Giorgio V. Scagliotti, Ugo Pastorino, et al. · Journal of Clinical Oncology · 274

Lowering of Microalbuminuria in Diabetic Patients by a Sympathicoplegic Agent

2001 · KRZYSZTOF STROJEK, WLADYSLAW GRZESZCZAK, et al. · Journal of the American Society of Nephrology · 112

A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

2013 · Wolfgang H.W. Schuette, Andreas Gröschel, et al. · Clinical Lung Cancer · 48

Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta

1996 · Kerstin Breithaupt-Grögler, Monika Leschinger, et al. · Cardiovascular Drugs and Therapy · 33

A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer

2014 · Christian Dittrich, Zsolt Papai-Szekely, et al. · European Journal of Cancer · 29

Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans

2003 · Esther B. Bachli, Stephan R. Vavricka, et al. · Intensive Care Medicine · 22

Pemetrexed in the treatment of malignant mesothelioma: Results from an expanded access program in Germany

2009 · Martin Reck, Rolf A. Stahel, et al. · Respiratory Medicine · 18

Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)

2010 · Helge G. Bischoff, Ben van den Borne, et al. · Current Medical Research and Opinion · 16

A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC.

2011 · J. Von Pawel, Z. Papai-Szekely, et al. · Journal of Clinical Oncology · 15

Pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in early-stage NSCLC

2009 · G. Schmid-Bindert, A. Chemaissani, et al. · Journal of Clinical Oncology · 12

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer

2013 · Gerald Schmid-Bindert, Vittorio Gebbia, et al. · Lung Cancer · 11

Gemcitabin in der First-line-Therapie des lokal fortgeschrittenen und metastasierten nicht-kleinzelligen Bronchialkarzinoms (NSCLC): Ergebnisübersicht randomisierter Phase-III-Studien

2005 · Monika I. Leschinger, Karin Helsberg, et al. · Oncology Research and Treatment · 6

PD-066 Does reporting expected duration and severity of adverseevents provide clinically relevant information when selecting a chemotherapy regimen? An example using pemetrexed and docetaxel

2005 · S. Bhalla, N. Thatcher, et al. · Lung Cancer · 4

Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer.

2010 · S. Nagel, A. Groeschel, et al. · Journal of Clinical Oncology · 2

9079 Pemetrexed in combination with cisplatin or carboplatin in the first line therapy of locally advanced or metastatic non-small cell lung cancer: a randomized, two-arm, parallel, open-label, multicentric phase 2 study

2009 · W. Schuette, A. Groeschel, et al. · European Journal of Cancer Supplements · 1

Palliative chemotherapy of non-small cell lung cancer (NSCLC): Baseline data analysis of the ACTION observational study in 5 European countries

2005 · H. Bischoff, H. Anderson, et al. · Journal of Clinical Oncology · 1

Aortic Compliance in Hypertension–Effects of Cilazapril and Hydrochlorothiazide Can Be Distinguished

1992 · MedKerstin Breithaupt, Monika Leschinger, et al. · Blood Pressure · 1

Phase II study of pemetrexed (Pem) and cisplatin (Cis) plus cetuximab (Cet) followed by Pem and Cet maintenance therapy in patients (Pts) with advanced nonsquamous non-small cell lung cancer (NSCLC).

2012 · Gerald Schmid-Bindert, Vittorio Gebbia, et al. · Journal of Clinical Oncology

A randomized phase 2 study of pemetrexed vs. pemetrexed+erlotinib in second-line treatment for locally advanced or metastatic, non-squamous NSCLC

2012 · J von Pawel, Z Papai-Szekely, et al. · Pneumologie

PD4-3-2: Observing who performance status of patients undergoing chemotherapy for advanced non-small cell lung cancer (NSCLC)

2007 · Ben van den Borne, Helge G. Bischoff, et al. · Journal of Thoracic Oncology

Observing patients with advanced non-small cell lung cancer (NSCLC): An overview of real world treatments and outcomes in Europe

2007 · H. G. Bischoff, H. Anderson, et al. · Journal of Clinical Oncology

P-458 Palliative chemotherapy of non-small cell lung cancer (NSCLC): Analysis of German baseline data from the ACTION observational study

2005 · H. Bischoff, M. Leschinger, et al. · Lung Cancer

Do the published toxicity data from clinical trials in oncology give the full picture? An example using pemetrexed and docetaxel

2005 · G. Stynes, U. Gatzemeier, et al. · Journal of Clinical Oncology

Bewertung der Kosten und Ergebnisse der Chemotherapie bei Patienten mit fortgeschrittenem NSCLC im Rahmen einer Anwendungsbeobachtung (ACTION)

2005 · HG Bischoff, M Thomas, et al. · Pneumologie

Works count: 24

Citation count: 605

H-index: 11

I10-index: 11